PDS Biotechnology (PDSB)
(Delayed Data from NSDQ)
$2.95 USD
-0.01 (-0.34%)
Updated May 30, 2024 04:00 PM ET
After-Market: $2.96 +0.01 (0.34%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PDSB 2.95 -0.01(-0.34%)
Will PDSB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PDSB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PDSB
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
PDSB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
Other News for PDSB
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024
Buy Rating Affirmed for PDS Biotechnology on Strong Financials and Promising Clinical Pipeline
PDS Biotechnology: Q1 Earnings Snapshot
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results